What is Going on With These Falling Stocks?

Catabasis Pharmaceuticals Inc (NASDAQ:CATB)’s shares have slid by 15% on the back of the company announcing that it has priced the offering of 2.5 million shares at $4 a piece. The company will use the net proceeds to fund ongoing and planned clinical trials of edasalonexent (CAT-1004), R&D for other potential drugs, and general corporate purposes, among other activities. Only three funds from our database had a bullish position in Catabasis Pharmaceuticals Inc (NASDAQ:CATB) at the end of the second quarter, unchanged from the previous quarter.

Oshkosh Corp (NYSE:OSK) is 6% in the red after the company (on its analyst day) raised its full fiscal 2016 adjusted EPS guidance to $2.85-$3 from the previous $2.60-$2.8. Oshkosh also raised the corresponding revenue guidance to $6.1-$6.2 billion from the previous $6-$6.1 billion. Although that is better than expected by analysts, shares are down in part because the company expects an EPS impact of $0.23 in fiscal 2016 for restructuring charges. Oshkosh Corp (NYSE:OSK)’s fiscal 2017 revenue guidance of $6.5-$6.7 billion is not that impressive, when compared to the average estimate of $6.66 billion. The smart money became a little bit more optimistic on Oshkosh Corp in the second quarter. The number of investors tracked by us with holdings in Oshkosh Corp (NYSE:OSK) rose by six quarter-over-quarter to 16 at the end of June.

Wix.Com Ltd (NASDAQ:WIX) has fallen by around 5% after RBC Capital downgraded the stock to ‘Sector Perform’ from ‘Outperform’ mainly for valuation reasons. Shares of Wix.Com have almost doubled year-to-date. The analysts have a $45 price target on the stock. At the end of the second quarter, 19 investors from our database owned shares of Wix.Com Ltd (NASDAQ:WIX), compared to 13 funds at the end of March.

Disclosure: none